HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), a company primarily focused on leveraging its novel and proprietary CellFX Nanosecond Pulsed Field Ablation (nsPFA) technology ...
Company’s proprietary system used to treat initial five patients in first-in-human feasibility study for patients with atrial fibrillation HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc.
Zacks Investment Research on MSN
PLSE shares positive first-in-human nPulse cardiac catheter data
Pulse Biosciences PLSE recently announced late-breaking data from its first-in-human feasibility study of the nPulse Cardiac ...
一些您可能无法访问的结果已被隐去。
显示无法访问的结果